GlassScriptPhysician profile
Tamara Khazbieva
NPI 1477225837
$3,558.90
in general payments reported to CMS, 2019-2025
42 companies · $684 in 2025
The $684 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,054 · 2023: $1,124 · 2024: $697 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.10 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $305.85 | 2022-2025 | |
| Amgen INC. | $274.22 | 2022-2023 | Vectibix, Xgeva, Nplate |
| Merck Sharp & Dohme LLC | $228.23 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $227.83 | 2022-2025 | Iclusig, Fruzaqla |
| Genentech USA, INC. | $202.03 | 2023-2024 | Alecensa, Tecentriq, Rozlytrek |
| Janssen Biotech, INC. | $167.12 | 2022-2024 | Darzalex, Talvey, Tecvayli |
| Incyte Corporation | $164.61 | 2022-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $146.19 | 2022-2025 | Imfinzi, Enhertu |
| Tempus Ai, INC | $146.09 | 2025 | Xt Cdx |
| Celgene Corporation | $129.73 | 2022-2024 | Pomalyst, Reblozyl |
| Astellas Pharma US INC | $103.26 | 2022-2025 | Xtandi |
| Aveo Pharmaceuticals, INC. | $100.61 | 2022-2025 | |
| Genzyme Corporation | $98.66 | 2022-2024 | |
| Pfizer INC. | $96.32 | 2022-2024 | |
| Seagen INC. | $89.99 | 2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $79.04 | 2022-2025 | |
| Daiichi Sankyo INC. | $73.51 | 2023-2025 | Enhertu, Injectafer |
| Sobi, INC | $65.16 | 2022-2023 | |
| Eisai INC. | $60.73 | 2022-2024 | |
| Tersera Therapeutics LLC | $56.13 | 2023-2025 | Zoladex |
| Glaxosmithkline, LLC. | $55.30 | 2022-2023 | Ojjaara, Shingrix |
| Exelixis INC. | $54.05 | 2022-2024 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $52.63 | 2023-2024 | Opdivo, Krazati |
| Morphosys, US INC. | $49.60 | 2022-2023 | Monjuvi |
| Genmab U.S., INC. | $48.87 | 2023-2025 | Epkinly |
| Blueprint Medicines Corporation | $41.96 | 2022-2024 | Ayvakit |
| Lilly USA, LLC | $41.59 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
| Ipsen Biopharmaceuticals, INC | $41.39 | 2023-2024 | Somatuline Depot, Onivyde |
| Regeneron Healthcare Solutions, INC. | $38.86 | 2023 | Libtayo |
| Beigene USA, INC. | $36.80 | 2022-2023 | Brukinsa |
| Pharmaessentia USA Corporation | $36.15 | 2022-2023 | Besremi |
| Array Biopharma INC | $33.44 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Emmaus Medical, INC. | $32.17 | 2023 | Endari |
| Taiho Oncology, INC. | $25.84 | 2024 | |
| Ethicon INC. | $25.60 | 2025 | Monarch Platform |
| Geron Corporation | $23.03 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $20.90 | 2023 | Odomzo |
| Sumitomo Pharma America, INC. | $19.36 | 2023 | Orgovyx |
| G1 Therapeutics, INC. | $18.64 | 2023 | Cosela |
| Emd Serono, INC. | $17.25 | 2023 | Tepmetko |
| Immunogen, INC. | $16.24 | 2023 | Elahere |
| Servier Pharmaceuticals LLC | $13.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Khazbieva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.